Short Interest in Harvard Bioscience, Inc. (NASDAQ:HBIO) Declines By 32.3%

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the recipient of a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 453,726 shares, a drop of 32.3% from the February 12th total of 670,309 shares. Based on an average trading volume of 252,937 shares, the days-to-cover ratio is presently 1.8 days. Currently, 1.3% of the company’s stock are sold short. Currently, 1.3% of the company’s stock are sold short. Based on an average trading volume of 252,937 shares, the days-to-cover ratio is presently 1.8 days.

Institutional Trading of Harvard Bioscience

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE increased its holdings in shares of Harvard Bioscience by 44.4% in the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after acquiring an additional 11,948 shares in the last quarter. Acadian Asset Management LLC grew its position in shares of Harvard Bioscience by 7.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock valued at $606,000 after purchasing an additional 78,276 shares during the period. Strs Ohio bought a new stake in Harvard Bioscience during the 1st quarter worth approximately $117,000. Marshall Wace LLP acquired a new stake in Harvard Bioscience during the 2nd quarter worth approximately $61,000. Finally, Jane Street Group LLC lifted its stake in Harvard Bioscience by 491.9% in the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 58,785 shares in the last quarter. 80.87% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on HBIO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Monday, December 29th. Zacks Research raised Harvard Bioscience to a “hold” rating in a research note on Thursday, December 11th. Wall Street Zen upgraded Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Monday, November 17th. Benchmark lowered their price target on Harvard Bioscience from $2.00 to $0.60 and set a “speculative buy” rating for the company in a research note on Friday. Finally, New Street Research set a $0.60 price objective on Harvard Bioscience in a report on Friday. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Harvard Bioscience currently has an average rating of “Hold” and an average price target of $0.60.

Harvard Bioscience Stock Down 4.1%

HBIO stock traded down $0.02 during midday trading on Friday, reaching $0.47. The company’s stock had a trading volume of 486,469 shares, compared to its average volume of 337,769. The business’s 50-day simple moving average is $0.57 and its 200-day simple moving average is $0.57. Harvard Bioscience has a 52 week low of $0.28 and a 52 week high of $0.95. The stock has a market cap of $2.12 million, a PE ratio of -0.37 and a beta of 1.51.

Harvard Bioscience shares are set to reverse split on Monday, March 16th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, March 15th.

Harvard Bioscience News Roundup

Here are the key news stories impacting Harvard Bioscience this week:

• Positive Sentiment: High margins and margin-first guidance — Q4 gross margin was ~59.7% and management emphasized a high‑margin focus and structural improvements for 2026, which supports higher long‑term profitability if execution continues. GlobeNewswire: Q4 results
• Positive Sentiment: Revenue beat and modest growth outlook — Q4 revenue ($23.7M) slightly exceeded consensus and the company issued 2026 revenue guidance calling for ~2%–4% growth driven by new products for translational science, indicating gradual recovery potential. Seeking Alpha: 2026 guidance
• Positive Sentiment: C-suite stability — Interim CFO Mark Frost was appointed permanent CFO, reducing near‑term leadership uncertainty. GlobeNewswire: CFO appointment
• Neutral Sentiment: Reverse split scheduled — A 1-for-10 reverse split will take effect March 16th; this addresses low per‑share price and listing considerations but does not change the company’s fundamentals. American Banking News: Reverse split
• Negative Sentiment: EPS miss and weak profitability metrics — Q4 EPS was ($0.01) vs. a $0.04 estimate; the company reported a negative net margin (~-61.6%) and negative ROE, which helps explain selling pressure despite the revenue beat. MarketBeat: Earnings details
• Negative Sentiment: Analyst price‑target cut — Benchmark lowered its PT from $2.00 to $0.60 (but kept a “speculative buy” stance), reducing visible upside from earlier projections and likely weighing on sentiment. StreetInsider: PT lowered

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.